1. Market Research
  2. > Pharmaceutical Market Trends
Global Uveitis Treatment Market By Drug Class By Disease Type By Distribution Channel By Region, Industry Analysis and Forecast, 2019 - 2025

Global Uveitis Treatment Market By Drug Class By Disease Type By Distribution Channel By Region, Industry Analysis and Forecast, 2019 - 2025

  • March 2020
  • 214 pages
  • ID: 5885928
  • Format: PDF
  • KBV Research

Summary

Table of Contents

The Global Uveitis Treatment Market size is expected to reach $686.1 Million by 2025, rising at a market growth of 5.5% CAGR during the forecast period. Uveitis is the inflammation of the middle tissue layer in the uvea eyewall which consists of the iris, choroid, and ciliary body. Various drug formulations such as anti-inflammatory drugs, cycloplegic agents, antimicrobial drugs, immunotherapy & targeted therapies, and others are used for uveitis treatment. These involve anterior uveitis, intermediate uveitis, posterior uveitis, and panuveitis. Inflammation of the iris called iritis or anterior uveitis is the most prevalent form of uveitis.

Increased prevalence of uveitis and growing awareness among the patient population with increased acceptance of innovative treatments is expected to drive the growth of the market. In addition, convenient access to uveitis treatment, increased demand for uveitis medications, and a boom in R&D activities to improve ideal uveitis treatment to further drive the growth of the industry.

Nevertheless, it is anticipated that the uncertain etiology and pathophysiology of uveitis would hinder market development. In addition, untapped capacity offered by emerging economies is presenting lucrative opportunities for market growth over the forecast period. Nonetheless, there is likely to be a shortage of effective treatment for uveitis disorder to limit the market growth.

Uveitis is considered the leading cause of blindness in the United States, with a steady rise in prevalence. Corticosteroid is considered the first-line treatment for uveitis. A large number of compounds for treating uveitis are lined up in growth. Leading industry players are adding new drugs to improve their product portfolio. The procedure for the sterile formulations, however, is highly complex and businesses are likely to align themselves with the GMP and regulatory requirements for producing their products.

Based on Drug Class, the market is segmented into Anti-inflammatory, Immunotherapy & Targeted Therapies, Antimicrobial Drugs and Other Drug Class. Based on Disease Type, the market is segmented into Anterior Uveitis, Posterior Uveitis, Intermediate Uveitis and Panuveitis. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online stores. Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AbbVie, Inc., Alimera Sciences, Inc., Enzo Biochem, Inc., Amgen, Inc., Bausch Health Companies, Inc., Clearside Biomedical, Inc., EyePoint Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., TopiVert Ltd., and Novartis AG.

Strategies deployed in Uveitis Treatment Market

Mar-2020: Clearside Biomedical announced an agreement with Arctic Vision, a company focused on developing and commercializing innovative ophthalmology therapies in China and Asia. Under this agreement, the latter company has acquired an exclusive license for the commercialization and development of XIPERE (triamcinolone acetonide suprachoroidal injectable suspension) in Greater China (mainland China, Hong Kong, Macau and Taiwan) and South Korea.

Feb-2020: Santen Pharmaceutical signed an agreement with Verily, an Alphabet company. Following the agreement, the companies would establish a joint venture focused on applying microelectronics and scalable digital technologies to ophthalmology.

Oct-2019: Bausch Health Ireland signed an agreement with Clearside Biomedical. The agreement granted Bausch with an exclusive license for developing, manufacturing, distributing, promoting, marketing, and commercializing the suprachoroidal injection device.

Sep-2019: Alimera Sciences launched ILUVIEN in Germany. This solution has been used in prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIPU).

Jul-2019: Novartis completed the acquisition of Xiidra (lifitegrast ophthalmic solution), the first and only prescription treatment approved to treat both signs and symptoms of dry eye by inhibiting inflammation caused by the disease. The acquisition enabled the company to deliver medicine for patients suffering from a variety of eye diseases.

Mar-2019: Novartis got FDA approval for Mayzent (siponimod), a new solution for the treatment of relapsing forms of multiple sclerosis (RMS).

Feb-2019: EyePoint Pharmaceuticals released the Yutiq, a 3-year micro-insert for the treatment of chronic noninfectious uveitis, which affects the posterior segment of the eye. The company also announced the launch of EyePoint Assist, a program for ensuring access to Yutiq for eligible patients in need of financial assistance.

Oct-2018: Amgen introduced Amgevita in Europe. This therapy is available in the 28 countries of the European Union, plus Norway, Iceland, and Liechtenstein. Amgevita is a human antibody that has been designed for targeting the human tumor necrosis factor alpha (TNF?), an immune factor that regulates the inflammatory response.

Mar-2018: pSivida acquired Icon Bioscience and its FDA-approved dexamethasone intraocular suspension designed to treat postoperative inflammation. Following the acquisition, both the companies have combined their businesses and started doing business as EyePoint Pharmaceuticals.

Jul-2016: AbbVie got FDA approval for Humira, a new therapy for non-infectious intermediate, posterior, and panuveitis. This is a non-corticosteroid treatment option for certain types of uveitis, an eye disease that can flare and impact vision.

Scope of the Study

Market Segmentation:

By Drug Class

• Anti-inflammatory

• Immunotherapy & Targeted Therapies

• Antimicrobial Drugs

• Other Drug Class

By Disease Type

• Anterior Uveitis

• Posterior Uveitis

• Intermediate Uveitis

• Panuveitis

By Distribution Channel

• Hospital Pharmacies

• Retail Pharmacies

• Online stores

By Geography

• North America

o US

o Canada

o Mexico

o Rest of North America

• Europe

o Germany

o UK

o France

o Russia

o Spain

o Italy

o Rest of Europe

• Asia Pacific

o China

o Japan

o India

o South Korea

o Singapore

o Malaysia

o Rest of Asia Pacific

• LAMEA

o Brazil

o Argentina

o UAE

o Saudi Arabia

o South Africa

o Nigeria

o Rest of LAMEA

Companies Profiled

• AbbVie, Inc.

• Alimera Sciences, Inc.

• Enzo Biochem, Inc.

• Amgen, Inc.

• Bausch Health Companies, Inc.

• Clearside Biomedical, Inc.

• EyePoint Pharmaceuticals, Inc.

• Santen Pharmaceutical Co., Ltd.

• TopiVert Ltd.

• Novartis AG

Unique Offerings

• Exhaustive coverage

• Highest number of market tables and figures

• Subscription based model available

• Guaranteed best price

• Assured post sales research support with 10% customization free

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Cholesteryl Ester Transfer Protein - Pipeline Review, H2 2020

  • $ 3500
  • October 2020
  • 50 pages

Cholesteryl Ester Transfer Protein - Pipeline Review, H2 2020 Summary According to the recently published report ’Cholesteryl Ester Transfer Protein - Pipeline Review, H2 2020’; Cholesteryl Este ...

  • World
  • Cardiovascular Disease
  • Cholesterol
  • Industry analysis
  • Cause-Specific Mortality Rate
  • Pharmaceutical Registrations

ref:plp2020

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on